TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Acetaminophen/Naproxen Sodium Dose Ranging Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 17-50 years old~2. Weigh 100 pounds or greater and have a body mass index (BMI) of 17.5-35.4 (inclusive) at screening~3. Surgical removal of three or four third molars, of which, two must be mandibular impactions~4. Meets requirements for post-surgical pain level~5. Females of childbearing potential and males agree to contraceptive requirements of study~6. Have a negative urine drug screen at screening, and on day of surgical procedure~Exclusion Criteria:~1. Pregnant female, breastfeeding, trying to become pregnant or male with pregnant partner or partner currently trying to become pregnant~2. Have a known allergy or hypersensitivity to naproxen or other NSAIDs, including aspirin, or to acetaminophen, oxycodone or other opioids;~3. Not able to swallow whole large tablets or capsules~4. History of any condition (s) in investigator's opinion, may jeopardize subject safety, well-being and integrity of study~5. Use analgesics 5 or more times per week~6. History of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the investigator site staff, in the last 5 years~7. Use of any immunosuppressive drugs within 2 weeks of screening~8. History of endoscopically documented peptic ulcer disease or bleeding disorder in the last 2 years

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Acetaminophen/naproxen sodium Dose A (Type: EXPERIMENTAL): Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
- Acetaminophen/naproxen sodium Dose B (Type: EXPERIMENTAL): Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
- Acetaminophen/naproxen sodium Dose C (Type: EXPERIMENTAL): Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
- Acetaminophen/naproxen sodium Dose D (Type: EXPERIMENTAL): Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
- Acetaminophen/naproxen sodium Dose E (Type: EXPERIMENTAL): Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets administered as a single two-tablet dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Healthy males or females subjects~* Age 18 to 50 years (incl.)~* Body mass index (BMI) 18.5 to 29.9 kg/m2 (incl.)~* Signed and dated written informed consent prior to admission to the study~Exclusion criteria:~* Any finding in the medical examination (including blood pressure, pulse rate or ECG) deviating from normal and judged clinically relevant by the investigator.~* Systolic blood pressure (BP) less than 100 mmHg and more than 140 mmHg.~* Diastolic BP less than 60 mmHg and more than 90 mmHg.~* Pulse rate (PR) less than 50 bpm and more than 90 bpm.~* Any laboratory value outside the reference range that the investigator considers to be of clinical relevance~* Any evidence of a concomitant disease judged clinically relevant by the investigator~* Positive QuantiFERON-TB Gold In-Tube

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 Cyclosporine + Faldaprevir (Type: EXPERIMENTAL): None
- 2 Tacrolimus + Faldaprevir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Physical Activity In High Poverty Neighborhoods

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: Parks are in low-income neighborhoods; individuals visit parks and/or live within 1 mile radius of the park; -~Exclusion Criteria: Parks are not in low income neighborhoods; individuals do not visit the park and do not live within a 1 mile radius~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Frequent User Arm (Type: EXPERIMENTAL): Park users will be able to earn rewards or prizes by coming more frequently to the park
- Free Physical Activity Classes/programs (Type: EXPERIMENTAL): We will offer at least 100 free physical activity classes at the park
- Combined arm (Type: EXPERIMENTAL): We will offer free classes and the frequent user program at the park
- Control (Type: NO_INTERVENTION): Business as usual, no special physical activity programs offered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who has completed the scheduled visits, including the End-of-Study Visit, in Study CT-P13 1.1~* Patient who has not had any major protocol violation in Study CT-P13 1.1~Exclusion Criteria:~* Patient who has been withdrawn from Study CT-P13 1.1 for any reason~* Patient who, at the time of providing informed consent, has any ongoing medical issues such as serious adverse events(SAEs) or intolerance issues that mean continuation in this extension study could be detrimental to their health, in the option of the investigator~* Patient who plans to participate in a study with an investigational drug during the period of this extension study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 (Type: ACTIVE_COMPARATOR): infliximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children who participated in NOVA study and are of school age~Exclusion Criteria:~* Children who participated in NOVA study but deceased post discharge

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled nitric oxide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Dexmedetomidine for Sedated Hearing Testing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Child aged 1 to 15 years old~* American Society Anesthesiologists (ASA) scale patient 1 or 2~* Need to evaluate the child audition in a context of suspicion of deafness, delay of language, global delay of the development, the risk factors of hearing loss~* Impossibility to realize a hearing test by conventional audiogram or behavioral due to a cognitive or behavioral disorder of the child~* Affiliation to social security scheme~* Signature of the authorization documents of the 2 parents or the representative of the parental authority for the participation of the child in the study~Exclusion Criteria:~* Heart disease or heart rhythm disorder~* Pneumopathy or asthmatic crisis in previous 2 weeks in the examination~* Recent used of digoxine or beta-blocker~* Use of anti-epileptic or psychotropic drugs~* Medical history of sleep apnea~* Receptor alpha2 agonist allergy~* Gastrooesophageal reflux disease~* Upper airway abnormality~* Acute cerebrovascular diseases~* Neurologic disorders ( cranial trauma and after neurosurgical operation)~* Recent cerebral vascular accident~* Moyamoya disease~* General anesthesia planned for another procedure

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine Hydrochloride (Type: EXPERIMENTAL): sedation of patients to perform auditory test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of stage IIIB, IIIC or IVM1a melanoma eligible for complete surgical resection.~* Prior systemic, regional and radiation anticancer therapies for melanoma must have been completed at least 3 months prior to randomization.~* Subject must have measurable disease and must be a candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (≥ 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of ≥ 10 mm.~* Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and must have a serum lactate dehydrogenase (LDH) ≤ 1.0 X upper limit of normal and adequate hematologic, hepatic, renal, and coagulation organ function- Other criteria may apply~Exclusion Criteria:~* Subject must not have primary ocular or mucosal melanoma, or history or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia).~* Subject must not have history or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease.~* Subject must not have evidence of clinically significant immunosuppression or active herpetic skin lesions or prior complications of herpes simplex type 1 (HSV-1) infection (eg, herpetic keratitis or encephalitis) and must not require intermittent or chronic systemic treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use.~* Subject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded.~* Subject must not have been treated previously with talimogene laherparepvec or tumor vaccine.~Other criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery (Type: OTHER): Surgical resection of melanoma tumor lesion(s)
- Talimogene Laherparepvec (Type: EXPERIMENTAL): Talimogene laherparepvec for 6 doses followed by surgical resection of melanoma tumor lesion(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Anti-venoms Serum in Africa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient over 5 years old (inclusive) visiting at a participating center for a snake bite with or without confirmed envenoming~* Informed consent to research~Exclusion Criteria:~* Patient refusal~* Under 5 year-old~* Antivenom serum administration before the arrival in the participating center~* History of severe allergic reactions to antivenom serum

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients bitten by a snake (Type: None): Any patient over 5 years old going to a participating center for curative care following a snake bite.~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Children and adolescents with type 2 diabetes mellitus~* Insufficient glycaemic control (HbA1c \<=10.5%) despite diet and exercise and/or metformin and/or stable basal or MDI insulin~* Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and fasting C-peptide levels \>= 0.85 ng/ml~* BMI \> 50th percentile for age and sex~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \> 240 mg/dl (\> 13.3 mmol/l)~* History of acute metabolic decompensation such as diabetic ketoacidosis within 3 months before the screening visit with the exception of acute de-compensation at the time of type 2 diabetes diagnosis~* Treatment with weight reduction medications within 4 weeks before randomisation

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- empagliflozin high dose (Type: EXPERIMENTAL): Patient to receive a high dose of empagliflozin
- empagliflozin medium dose (Type: EXPERIMENTAL): Patient to receive a medium dose of empagliflozin
- empagliflozin low dose (Type: EXPERIMENTAL): Patient to receive a low dose of empagliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Sertraline on Brain Connectivity in Adolescents With OCD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (OCD):~* OCD as the primary Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis based on the Anxiety Disorders Interview Schedule (ADIS) for DSM-IV, Child Version~* Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score of greater than 15~Exclusion Criteria (OCD):~* lifetime diagnosis of bipolar disorder, schizophrenia, or substance abuse/dependence on ADIS~* Intelligence Quotient (IQ) \< 80 on Wechsler Abbreviated Scales of Intelligence (WASI)~* positive urine drug screen~* MRI-incompatible features (e.g., metal implants, claustrophobia)~* current or recent trial of psychotropic medication (within the past 4 8 weeks or past 6 12 weeks for fluoxetine)~* non-response in \> 2 selective serotonin reuptake inhibitor (SSRI) trials of adequate dose/duration~* positive pregnancy test~* history of seizure disorder or serious head injury~Inclusion Criteria (Controls):~* Healthy 8-17 year olds~Exclusion criteria (controls):~* No psychiatric diagnoses~* No immediate family history of OCD

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Children with OCD (Type: EXPERIMENTAL): Children with obsessive compulsive disorder, not currently on medication for OCD
- Healthy Control Children (Type: ACTIVE_COMPARATOR): Children without obsessive compulsive disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in Japan with the indication of Fabry Disease and for whom the usual dosage and administration is 1mg of agalsidase beta (recombinant) per 1 kg body weight each time, administered by intravenous infusion every 2 weeks~* Because the efficacy evaluation of enzyme replacement therapy with Fabrazyme \[agalsidase beta (recombinant form)\] will require the comparison of findings before and after the start of enzyme replacement therapy, the efficacy evaluation set will be defined as including patients using Fabrazyme \[agalsidase beta (recombinant form)\] for the first time in the post-marketing setting and those for whom it is possible to obtain retrospective data for before the start of enzyme replacement therapy.~Exclusion Criteria:~* Patients registered in the post-marketing trials during the post-marketing clinical trial period.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female subjects~* 18 years of age or older~* Received aspirin, clopidogrel, heparin (unfractionated or low molecular weight \[LMW\]) and eptifibatide~* Had a successful PCI procedure with at least one stent deployed~* Availability of a hospital bed~Exclusion Criteria:~* Use of alternative anti-thrombin therapy during PCI (e.g. bivalirudin)~* High risk patients:~* Acute ST elevation MI \< 48 hours (either direct PCI or rescue PCI)~* Unprotected left main PCI~* Obvious large thrombus on angiography~* Use of rotablation, atherectomy, or thrombectomy devices~* Unsatisfactory PCI results:~* Final thrombolysis in myocardial infarction (TIMI) flow \< 3~* High grade dissection (\> type B, if not completely resolved at completion of PCI)~* Evident or suspected thrombus~* Distal embolization~* Suboptimal stenting (\> 20% residual stenosis)~* Side branch closure (≥ 1.5 mm branch or with associated symptoms)~* Abrupt closure during procedure (if prolonged \> 15 min or not resolved at completion of PCI)~* Clinical instability~* Prolonged ischemia during PCI (\> 15 min)~* Increased hazard of eptifibatide infusion:~* Unsatisfactory deployment of a closure device (if used)~* Large peri-procedure hematoma making the continuation of eptifibatide hazardous~* Any condition that will increase the hazard of continuing eptifibatide~* Operator discretion~* No informed consent~* Active participation in other research studies (unless with special exemption)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18 Hour infusion (Type: ACTIVE_COMPARATOR): None
- 4 hour infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Supplement With and Without a Probiotic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults between the ages of 18-75 years~* Willingness to complete all study procedures and clinic visits, and provide required samples~* Provides informed consent~Exclusion Criteria:~* Women who are pregnant or breastfeeding, or intend to become pregnant during the course of this study~* Subjects with history of lactose intolerance~* Subjects who are on a PPI regimen~* Subjects who have taken a probiotic during the previous 30 days, or intends to take a probiotic during the study.~* Subjects who have taken antibiotics within 120 days~* Alcohol or drug abuse during the last 12 months, including passing a screen for drugs of abuse at screening~* Unstable medical condition, in the opinion of the investigator~* Clinically significant abnormal laboratory test results at screening~* Participation in a clinical research trial within 30 days prior to screening~* Unable to give informed consent~* Any condition which may preclude subject's ability to comply with and complete the study or may pose a risk to the health of the subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (PPI + probiotic) (Type: EXPERIMENTAL): Subjects in Cohort 1 will take a PPI and a probiotic orally once daily on Days 1-7. Subjects will mix the probiotic in an aqueous diluent supplied by the pharmacy and ingest between 1-2 hours after taking a PPI.
- Cohort 2 (Complex oligosaccharide + PPI) (Type: EXPERIMENTAL): Subjects in Cohort 2 will take the complex oligosaccharide orally twice daily on Days 1-14. On Days 1-7, the first dose of the complex oligosaccharide will be taken between 1-2 hours after taking a PPI. On Days 8-14, subjects will not take a PPI prior to the complex oligosaccharide.
- Cohort 3-6 (Complex oligosaccharide + PPI +probiotic) (Type: EXPERIMENTAL): Subjects in Cohort 3, 4, and 6 will take a complex oligosaccharide orally twice daily (doses will vary per cohort) on Days 1-14 in combination with a probiotic orally once daily on Days 1-7. Cohort 5 will undergo the same dosing regimen a second time on days 29-43

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete